[{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"DeGregorio Family Foundation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"Dendritic Cell Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beth Israel Deaconess Medical Center \/ DeGregorio Family Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Beth Israel Deaconess Medical Center \/ DeGregorio Family Foundation"},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Beth Israel Deaconess Medical Center \/ Johnson & Johnson","highestDevelopmentStatusID":"4","companyTruncated":"Beth Israel Deaconess Medical Center \/ Johnson & Johnson"},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"Quercis Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Isoquercitrin","moa":"sP-selectin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beth Israel Deaconess Medical Center \/ Quercis Pharma","highestDevelopmentStatusID":"9","companyTruncated":"Beth Israel Deaconess Medical Center \/ Quercis Pharma"}]

Find Clinical Drug Pipeline Developments & Deals by Beth Israel Deaconess Medical Center

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : The funding will be used for the development of a personalized dendritic cell/organoid-based vaccine for the treatment of patients with gastric cancer undergoing surgical resection.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          January 02, 2024

                          Lead Product(s) : Dendritic Cell Vaccine

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : DeGregorio Family Foundation

                          Deal Size : $0.5 million

                          Deal Type : Funding

                          blank

                          02

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : The patents cover the inhibition of soluble P-selectin that helps to prevent and/or reduce thrombotic events. Quercis’ lead drug candidate ISQ950AN, acts as an antithrombotic with significantly lower risk of adverse events than existing therapies.

                          Product Name : ISQ950AN

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 21, 2021

                          Lead Product(s) : Isoquercitrin

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Quercis Pharma

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          03

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : The parties have commenced preclinical testing of multiple vaccine prospects, with the aim to identify by the end of the month a COVID-19 vaccine candidate for clinical trials.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          March 13, 2020

                          Lead Product(s) : COVID-19 Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Johnson & Johnson

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank